Diagnosing TK2D: Clinical Red Flags and Genetic Testing First

"Diagnosing TK2D: Clinical Red Flags and Genetic Testing First" opens with the human cost of diagnostic delay and moves to practical testing decisions.

Dr. Hirano asks how the loss of motor milestones affects caregivers. Dr. Zolkipli-Cunningham says it is shocking for parents of a child who was developing normally or only slightly slowly. She has seen children abruptly lose independent walking, which can prompt a workup for neurodegenerative disorders, typically seen around ages three to five. Time to diagnosis can be delayed while clinicians weigh whether the problem arises in brain or muscle. Genetic testing is now first-line for spinal muscular atrophy and neurodegenerative disorders alike, and expedited access could shorten the diagnostic odyssey. Dr. Hirano agrees completely that access is central.

Dr. Hirano asks about red flags that should prompt mitochondrial screening. Dr. Zolkipli-Cunningham says parents may not volunteer it, but asking often reveals a history of failure to thrive, short stature, low early growth percentiles, or slow weight gain, which signal an energy problem. Involvement of a second organ system, particularly mild or moderate gastrointestinal symptoms, suggests more than isolated muscle disease. Family history matters as well.

Genetic testing is the confirmatory test and needs sound justification, supported by CK, lactate, kidney and liver function, EKG, and echocardiogram. These supportive tests help build that justification, which is why pattern recognition of the symptoms matters. Without local access, she recommends referral to a genetics, mitochondrial disease, or neurology clinic. First-line testing is now whole exome or whole genome sequencing through CLIA-certified labs, billed to insurance, with established follow-up to discuss results.

She notes that both outcomes provoke anxiety. A TK2D diagnosis is hard to hear, yet a negative result leaves families of a symptomatic child without answers. Delivering results therefore requires care, thoughtfulness, and planning.

Up next, in "TK2D Muscle Biopsy and Genetic Testing Strategy: Panel or Exome," the experts ask whether a muscle biopsy still adds value when genetic results are uncertain, and how to choose between panels and exomes.